With the understanding of BRAF, RAS mutations, and RET/PTC rearrangements in thyroid cancer, researchers still need to identify the existence of unknown genetic or epigenetic alterations within the subpopulation of CSCs. This evidence concerns the gene RET and thyroid gland carcinoma.